{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:09:59Z","timestamp":1780614599795,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:00:00Z","timestamp":1570060800000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.oret.2018.04.009","type":"journal-article","created":{"date-parts":[[2018,6,2]],"date-time":"2018-06-02T18:30:38Z","timestamp":1527964238000},"page":"1021-1027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Atrophy in Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"2","author":[{"given":"Amithia","family":"Domalpally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald P.","family":"Danis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Trane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A.","family":"Blodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci E.","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-9802","authenticated-orcid":false,"given":"Emily Y.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2018.04.009_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2018.04.009_bib2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/archophthalmol.2010.92","article-title":"The prevalence of age-related macular degeneration and associated risk factors","volume":"128","author":"Klein","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2018.04.009_bib3","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S0161-6420(91)32186-9","article-title":"The Wisconsin age-related maculopathy grading system","volume":"98","author":"Klein","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.009_bib4","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1001\/archopht.123.11.1484","article-title":"The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report no. 17","volume":"123","author":"Davis","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2018.04.009_bib5","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2018.04.009_bib6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2018.04.009_bib7","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.009_bib8","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti\u2013vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.009_bib9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","article-title":"Macular morphology and\u00a0visual acuity in the second year of the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"123","author":"Sharma","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.009_bib10","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1167\/iovs.15-18572","article-title":"Drusen volume as a predictor of disease progression in patients with late age-related macular degeneration in the fellow eye","volume":"57","author":"Abdelfattah","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2018.04.009_bib11","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ajo.2015.02.020","article-title":"Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration","volume":"159","author":"Schutze","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2018.04.009_bib12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ophtha.2010.07.011","article-title":"Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials","volume":"118","author":"Rosenfeld","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.009_bib13","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/IAE.0000000000001059","article-title":"Progression of macular atrophy in patients with neovascular age-related macular degeneration undergoing antivascular endothelial growth factor therapy","volume":"36","author":"Abdelfattah","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.oret.2018.04.009_bib14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ophtha.2016.10.002","article-title":"Macular atrophy in neovascular age-related macular degeneration with monthly versus treat-and-extend ranibizumab: findings from the TREX-AMD trial","volume":"124","author":"Abdelfattah","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.009_bib15","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2147\/OPTH.S92359","article-title":"Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects","volume":"9","author":"Danis","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2018.04.009_bib16","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ajo.2015.01.032","article-title":"Macular atrophy progression and 7-year vision outcomes in subjects\u00a0from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study","volume":"159","author":"Bhisitkul","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2018.04.009_bib17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3928\/23258160-20160229-04","article-title":"Predictors of macular atrophy detected by fundus autofluorescence in patients with neovascular age-related macular degeneration after long-term ranibizumab treatment","volume":"47","author":"Kuehlewein","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2018.04.009_bib18","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.ophtha.2016.06.025","article-title":"Evaluation of geographic atrophy from color photographs and fundus autofluorescence images: Age-Related Eye Disease Study 2 report number 11","volume":"123","author":"Domalpally","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.009_bib19","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ophtha.2012.05.027","article-title":"The Age-Related Eye Disease Study 2 (AREDS2) study design and baseline characteristics (AREDS2 report number 1)","volume":"119","author":"Chew","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.009_bib20","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1167\/iovs.13-11804","article-title":"Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 report number 2)","volume":"54","author":"Danis","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2018.04.009_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.oret.2016.09.005","article-title":"Evolution of geographic atrophy in participants treated with ranibizumab for neovascular age-related macular degeneration","volume":"1","author":"Thavikulwat","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2018.04.009_bib22","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ophtha.2014.11.007","article-title":"Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials","volume":"122","author":"Grunwald","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.009_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and growth of geographic atrophy during 5 years of Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.009_bib24","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2018.04.009_bib25","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/IAE.0000000000001248","article-title":"Optical coherence tomography angiography of the foveal microvasculature in geographic atrophy","volume":"37","author":"Kvanta","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.oret.2018.04.009_bib26","article-title":"Macular atrophy findings by optical coherence tomography angiography compared with fundus autofluorescence in treated exudative age-related macular degeneration","author":"Takasago","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.oret.2018.04.009_bib27","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.ophtha.2015.08.015","article-title":"Association of baseline characteristics and early vision response with two-year vision outcomes in the Comparison of AMD Treatments Trials (CATT)","volume":"122","author":"Ying","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.009_bib28","doi-asserted-by":"crossref","first-page":"9497","DOI":"10.1167\/iovs.11-8346","article-title":"Blue-light versus green-light autofluorescence: lesion size of areas of geographic atrophy","volume":"52","author":"Wolf-Schnurrbusch","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2018.04.009_bib29","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ajo.2008.05.050","article-title":"The Epidemiology of Progression of Pure Geographic Atrophy. The Beaver Dam Eye Study","volume":"146","author":"Klein","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2018.04.009_bib30","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.ophtha.2013.03.029","article-title":"Incidence and progression of geographic atrophy: observations from a population-based cohort","volume":"120","author":"Joachim","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.04.009_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ajo.2017.07.009","article-title":"Treatment-Na\u00efve Quiescent Choroidal Neovascularization in Geographic Atrophy Secondary to Nonexudative Age-Related Macular Degeneration","volume":"182","author":"Capuano","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2018.04.009_bib32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ophtha.2017.08.030","article-title":"Natural History of Subclinical Neovascularization in Nonexudative Age-Related Macular Degeneration Using Swept-Source OCT Angiography","volume":"125","author":"de Oliveira Dias","year":"2018","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653018301210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653018301210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:24:41Z","timestamp":1762853081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653018301210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S2468653018301210"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2018.04.009","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atrophy in Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2018.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}